TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc. (the “Company” or “we”) is unable to timely file its Annual Report on Form 10-K for the year ended December 31, 2024 (the “Annual Report”) with the Securities and Exchange Commission (“SEC”) without unreasonable effort or expense. The Annual Report cannot be filed by the prescribed due date because additional time, resources and effort are required to complete work related to the Company’s financial reporting and close procedures, and to consider the significance of the errors identified in the Company’s fiscal quarterly results previously filed. The Company identified errors in the timing of stock-based compensation expense and clinical trial related research and development expenses and the use of incorrect assumptions. We are working diligently to evaluate the materiality of the errors to determine whether any corrections for previously disclosed 2024 quarterly results are required and to complete the Company’s year-end 2024 financial statements. In addition, the Company needs additional time to consider the significance of newly identified deficiencies associated with the errors. These deficiencies relate to material weaknesses associated with stock compensation and clinical trial prepaids and accruals. The Company anticipates that the Annual Report will be filed on or before the fifteenth calendar day following the prescribed due date. ______________________________________________________________________________

TriSalus Life Sciences, Inc. (the “Company” or “we”) is unable to timely file its Annual Report on Form 10-K for the year ended December 31, 2023 (the “Annual Report”) with the Securities and Exchange Commission (“SEC”) without unreasonable effort or expense. The Annual Report cannot be filed by the prescribed due date because additional time, resources and effort are required to complete work related to the Company’s financial reporting and close procedures, and to consider the significance of the errors identified in the Company’s fiscal third quarter results previously filed. The Company identified errors in determining its stock-based compensation expense for 2023 due in part to the Company’s transition to a new service provider in 2023 and the use of incorrect assumptions. We are working diligently to evaluate the materiality of the errors to determine whether any corrections for the third quarter financial results are required and to complete the Company’s year-end 2023 financial statements. In addition, the Company needs additional time to consider the significance of newly identified deficiencies associated with the errors. As a result of the continued evaluation, the Company’s independent registered accounting firm has been unable to complete its audit procedures. The Company anticipates that the Annual Report will be filed on or before the fifteenth calendar day following the prescribed due date

MedTech Acquisition Corporation (the “Company”) has determined that it is unable to file, without unreasonable effort and expense, its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 (the “Form 10-Q”) by the prescribed due date as a result of the reasons described below. The Company is considering the views expressed by the staff of the Securities and Exchange Commission (the “SEC Staff”) in a statement entitled “Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies” dated April 12, 2021 (the “SEC Staff Statement”) in which the SEC staff highlighted the potential accounting implication of certain terms that are common in warrants issued in connection with the initial public offerings of special purpose acquisition companies such as the Company. As a result of the SEC Staff Statement, the Company’s management is reevaluating the accounting treatment of (i) the 8,333,333 redeemable warrants that were included in the units issued by the Company in its initial public offering (the “Public Warrants”) and (ii) the 4,933,333 redeemable warrants that were issued in a private placement (the “Private Warrants”, collectively with the Public Warrants, the “Warrants”) in accordance with Accounting Standards Codification (“ASC”) 815-40, Derivatives and Hedging: Contracts in an Entities Own Equity. ASC 815-40 states entities must consider whether to classify contracts that may be settled in its own stock, such as warrants, as equity of the entity or as an asset or liability. The Company previously accounted for the Warrants as components of equity. After consideration of the SEC Staff Statement, the Company believes that the Warrants may need to be accounted for as a liability and measured at fair value with changes in fair value each period reported in the Company’s statement of operations. The Company is in the process of completing its final analysis of this change